A patient experiences muscle cramps and weakness during chemotherapy for lymphoma. Which cell surface markers will likely be absent from these neoplastic cells?

In this context, the patient is undergoing chemotherapy for lymphoma, which is a type of cancer that typically arises from lymphocytes, particularly B-cells and T-cells.

The neoplastic cells in lymphoma often exhibit specific surface markers that are characteristic of their lineage. B-cells usually express surface immunoglobulin (Ig), while T-cells express markers such as CD4 and CD8. If the patient has lymphoma that is derived from T-cells, you would expect the neoplastic cells to lack CD4 and CD8 expression, as they would have transformed and lost the typical markers associated with normal T-cell differentiation due to malignancy. Consequently, if the lymphoma is of T-cell origin, those surface markers would likely be absent.

In contrast, options involving MHC Class I, surface IgA, and CD34 do not directly pertain in the same way to the situation described. MHC Class I molecules are critical for presenting endogenous antigens to CD8+ T-cells and are commonly expressed unless there is a specific mechanism in tumor cells that downregulates them. Surface IgA, associated with B-cell differentiation, would not be absent in T-cell lymphomas and is characteristic of plasma cells. CD34 is a marker associated with